These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30634399)

  • 1. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.
    Lang L; Teng Y
    Cells; 2019 Jan; 8(1):. PubMed ID: 30634399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Gao L; Shay C; Lv F; Wang X; Teng Y
    Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
    Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making way for suppressing the FGF19/FGFR4 axis in cancer.
    Prieto-Dominguez N; Shull AY; Teng Y
    Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
    Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
    Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
    Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
    Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
    Mellor HR
    Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
    Hu L; Cong L
    Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
    Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L
    Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
    Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
    Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of fibroblast growth factor receptor 4 in cancer.
    Tang S; Hao Y; Yuan Y; Liu R; Chen Q
    Cancer Sci; 2018 Oct; 109(10):3024-3031. PubMed ID: 30070748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patent review of FGFR4 selective inhibition in cancer (2007-2018).
    Quintanal-Villalonga A; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Expert Opin Ther Pat; 2019 Jun; 29(6):429-438. PubMed ID: 31146605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
    Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
    Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
    Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
    J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?
    Heinzle C; Erdem Z; Paur J; Grasl-Kraupp B; Holzmann K; Grusch M; Berger W; Marian B
    Curr Pharm Des; 2014; 20(17):2881-98. PubMed ID: 23944363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
    Levine KM; Ding K; Chen L; Oesterreich S
    Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.